Opinion|Videos|August 9, 2024
Future Predictions for Intravenous and Subcutaneous Biologics
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- How has the introduction of IV biosimilars impacted your treatment decisions? Do you see a role for subcutaneous biosimilars in the future?
- Do you foresee IV and subcutaneous route of administration always having a role moving forward? How do you see the treatment landscape changing?
Advertisement
Related to this article
National Alliance names Jenny Goins interim CEO after former leader’s arrest; details emerge on charges, firing timeline, and impact on healthcare policy circles.
Only 19% use AI predictive models in cancer care despite strong belief in impact; 2026 Oncology Care Index highlights reimbursement, training, funding barriers.
Hispanic HIV incidence rose 16.8% in antisanctuary counties after the 2018 public charge announcement, relative to baseline counties, a new study found.
A review of randomized clinical trials, nonrandomized trials and case reports suggests that the inflammatory bowel disease risk from treatment with IL-17 inhibitors is low.
From a 95% remission rate in Japan to $81.6 billion in U.S. savings since 2015 — a data-driven look at where biosimilars stand today, and where the gaps remain.
AI pathology tool measures lung cancer treatment response after neoadjuvant chemoimmunotherapy with 91% accuracy, speeding NSCLC care while needing review for complete response.
A review of 57 studies found music eases pain through positive emotion, control and moving in time with the beat, according to recent research out of Drexel University.
UC San Diego researchers found that early-onset metabolic dysfunction-associated steatotic liver disease cirrhosis was linked to higher genetic risk and Type 2 diabetes prevalence.
Advertisement
Advertisement